Balancing treatments for patients with systemic hypertension and glaucoma

References

• Langman MJ, Lancashire RJ, Cheng KK, et al. Systemic hypertension and glaucoma: mechanisms in common and co-occurrence. Br J Ophthalmol. 2005;89(8):960–963.
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267.
   PubMed Web of Science ®Google Scholar
• Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–237.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):e13–e115.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Gandolfo F, Turano R, et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci. 2006;47(7):2917–2923.
   PubMed Web of Science ®Google Scholar
• Seibold LK, DeWitt PE, Kroehl ME, et al. The 24-Hour effects of Brinzolamide/Brimonidine fixed combination and timolol on intraocular pressure and ocular perfusion pressure. J Ocul Pharmacol Ther. 2017;33(3):161–169.
   PubMed Web of Science ®Google Scholar
• Drance SM, Crichton A, Mills RP. Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma. Am J Ophthalmol. 1998;125(5):585–592.
   PubMed Web of Science ®Google Scholar
• Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology. 1997;104(1):131–136.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Stewart JA, Jackson AL. Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. Acta Ophthalmol Scand. 2002;80(3):277–281.
   PubMedGoogle Scholar
• Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102(12):1743–1752.
   PubMed Web of Science ®Google Scholar
• Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978-1985. Am J Ophthalmol. 1986;102(5):606–611.
   PubMed Web of Science ®Google Scholar
• Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol. 1978;96(11):2045–2048.
   PubMedGoogle Scholar
• Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol. 2002;240(6):430–435.
   PubMed Web of Science ®Google Scholar
• Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology. 2000;107(6):1171–1177.
   PubMed Web of Science ®Google Scholar
• Vuori ML, Kaila T. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients. Graefes Arch Clin Exp Ophthalmol. 1995;233(3):131–134.
   PubMed Web of Science ®Google Scholar
• Tochikubo O, Minamisawa K, Miyakawa T, et al. Blood pressure during sleep: antihypertensive medication. Am J Cardiol. 1991;67(10):18B–25B.
   PubMed Web of Science ®Google Scholar
• Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996;41(Suppl 1):S27–37.
   PubMed Web of Science ®Google Scholar
• Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113(12):1514–1517.
   PubMedGoogle Scholar
• Konstas AG, Stewart WC, Topouzis F, et al. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am J Ophthalmol. 2001;131(6):729–733.
   PubMed Web of Science ®Google Scholar
• Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol. 1996;41(Suppl 1):S39–47.
   PubMed Web of Science ®Google Scholar
• Schettini C, Bianchi M, Nieto F, et al. Ambulatory blood pressure: normality and comparison with other measurements. Hypertension Working Group. Hypertension. 1999;34(4 Pt 2):818–825.
   PubMed Web of Science ®Google Scholar
• Muskens RP, Wolfs RC, Witteman JC, et al. Topical beta-blockers and mortality. Ophthalmology. 2008;115(11):2037–2043.
   PubMed Web of Science ®Google Scholar
• Letchinger SL, Frohlichstein D, Glieser DK, et al. Can the concentration of timolol or the frequency of its administration be reduced? Ophthalmology. 1993;100(8):1259–1262.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Katsanos A, Floriani I, et al. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52(10):1552–1557.
   PubMed Web of Science ®Google Scholar
• Laurence J, Holder D, Vogel R, et al. A double-masked, placebo-controlled evaluation of timolol in a gel vehicle. J Glaucoma. 1993;2(3):177–182.
   PubMedGoogle Scholar
• Shedden AH, Laurence J, Barrish A, et al. Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc Ophthalmol. 2001;103(1):73–79.
   PubMedGoogle Scholar
• Wandel T, Charap AD, Lewis RA, et al. Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol. 1986;101(3):298–304.
   PubMed Web of Science ®Google Scholar
• Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91(11):1361–1363.
   PubMed Web of Science ®Google Scholar
• Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis. Ophthalmology. 2016;123(1):129–140.
   PubMed Web of Science ®Google Scholar
• Allen RC, Hertzmark E, Walker AM, et al. A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. Am J Ophthalmol. 1986;101(5):535–541.
   PubMed Web of Science ®Google Scholar
• Schoene RB, Abuan T, Ward RL, et al. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol. 1984;97(1):86–92.
   PubMed Web of Science ®Google Scholar
• Dunn TL, Gerber MJ, Shen AS, et al. The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. Am Rev Respir Dis. 1986;133(2):264–268.
   PubMed Web of Science ®Google Scholar
• Netland PA, Weiss HS, Stewart WC, et al. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Am J Ophthalmol. 1997;123(4):465–477.
   PubMed Web of Science ®Google Scholar
• Stewart WC, Cohen JS, Netland PA, et al. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5% in patients with increased intraocular pressure. Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Am J Ophthalmol. 1997;124(4):498–505.
   PubMed Web of Science ®Google Scholar
• Adnet F, Plaisance P, Borron SW, et al. Prolonged severe hypercapnia complicating near fatal asthma in a 35-year-old woman. Intensive Care Med. 1998;24(12):1335–1338.
   PubMed Web of Science ®Google Scholar
• Le Jeunne CL, Hugues FC, Dufier JL, et al. Bronchial and cardiovascular effects of ocular topical B-antagonists in asthmatic subjects: comparison of timolol, carteolol, and metipranolol. J Clin Pharmacol. 1989;29(2):97–101.
   PubMed Web of Science ®Google Scholar
• Wu J, Jerng J, Su C. Insidious-onset, non-wheezing carteolol-induced asthma in an atopic patient without asthma history. BMJ Case Rep. 2019;12:e229343.
   Google Scholar
• Siesky B, Harris A, Ehrlich R, et al. Short-term effects of brimonidine/timolol and dorzolamide/timolol on ocular perfusion pressure and blood flow in glaucoma. Adv Ther. 2012;29(1):53–63.
   PubMed Web of Science ®Google Scholar
• Hommer A, Sperl P, Resch H, et al. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2012;28(6):569–575.
   PubMed Web of Science ®Google Scholar
• Feke GT, Rhee DJ, Turalba AV, et al. Effects of dorzolamide-timolol and brimonidine-timolol on retinal vascular autoregulation and ocular perfusion pressure in primary open angle glaucoma. J Ocul Pharmacol Ther. 2013;29(7):639–645.
   PubMed Web of Science ®Google Scholar
• Yuksel N, Altintas O, Karabas L, et al. The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma. Ophthalmologica. 1999;213(4):228–233.
   PubMed Web of Science ®Google Scholar
• Inoue K, Shiokawa M, Iwasa M, et al. Short-term efficacy and safety of a latanoprost/Carteolol fixed combination switched from concomitant therapy to in patients with primary open-angle glaucoma or ocular hypertension. J Glaucoma. 2018;27(12):1175–1180.
   PubMed Web of Science ®Google Scholar
• Asrani S, Robin AL, Serle JB, et al. Netarsudil/Latanoprost fixed-dose combination for elevated intraocular pressure: three-month data from a randomized Phase 3 trial. Am J Ophthalmol. 2019;207:248–257.
   PubMed Web of Science ®Google Scholar
• De Moraes CG, Liebmann JM, Greenfield DS, et al. Risk factors for visual field progression in the low-pressure glaucoma treatment study. Am J Ophthalmol. 2012;154(4):702–711.
   PubMed Web of Science ®Google Scholar
• Topouzis F, Wilson MR, Harris A, et al. Association of open-angle glaucoma with perfusion pressure status in the Thessaloniki Eye Study. Am J Ophthalmol. 2013;155(5):843–851.
   PubMed Web of Science ®Google Scholar
• Leske MC, Wu SY, Nemesure B, et al. Barbados Eye Studies G. Causes of visual loss and their risk factors: an incidence summary from the Barbados Eye Studies. Rev Panam Salud Publica. 2010;27(4):259–267.
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(11):1965–1972.
   PubMed Web of Science ®Google Scholar
• Melgarejo JD, Lee JH, Petitto M, et al. Glaucomatous optic neuropathy associated with nocturnal dip in blood pressure: findings from the Maracaibo Aging Study. Ophthalmology. 2018;125(6):807–814.
   PubMed Web of Science ®Google Scholar
• Kario K, Shimada K. Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens. 2004;26(2):177–189.
   PubMed Web of Science ®Google Scholar
• Fredric JG, Schuman JS. Reduced ocular hypotensive effect of topical beta blockers in glaucoma patients receiving oral beta blockers. J Glaucoma. 1992;1:174–177.
   Google Scholar
• Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol. 1995;113(1):77–83.
   PubMedGoogle Scholar
• O’Hare F, Jeganathan VS, Rokahr CG, et al. Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients. Clin Exp Ophthalmol. 2009;37(9):849–854.
   PubMed Web of Science ®Google Scholar
• Krupin T, Liebmann JM, Greenfield DS, et al. Low-Pressure Glaucoma Study G. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151(4):671–681.
   PubMed Web of Science ®Google Scholar
• Collaborative Normal Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126(4):487–497.
   PubMed Web of Science ®Google Scholar
• Miglior S, Torri V, Zeyen T, et al. Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol. 2007;144(2):266–275.
   PubMed Web of Science ®Google Scholar
• Muskens RP, de Voogd S, Wolfs RC, et al. Systemic antihypertensive medication and incident open-angle glaucoma. Ophthalmology. 2007;114(12):2221–2226.
   PubMed Web of Science ®Google Scholar
• Zheng W, Dryja TP, Wei Z, et al. Systemic medication associations with presumed advanced or uncontrolled primary open-angle glaucoma. Ophthalmology. 2018;125(7):984–993.
   PubMed Web of Science ®Google Scholar
• Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505–1516.
   PubMed Web of Science ®Google Scholar
• Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;385(9975):1295–1304.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738–745.
   PubMed Web of Science ®Google Scholar
• Baxter SL, Marks C, Kuo TT, et al. Machine learning-based predictive modeling of surgical intervention in glaucoma using systemic data from electronic health records. Am J Ophthalmol. 2019;208:30–40.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Smolensky MH, Mojón A, et al. New perspectives on the definition, diagnosis, and treatment of true arterial hypertension. Expert Opin Pharmacother. 2020 Jul;21(10):1167-1178. doi:10.1080/14656566.2020.1746274. Epub 2020 Jun 16. PMID: 32543325.
   Google Scholar